Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0YU1M
|
||||
| Former ID |
DIB011026
|
||||
| Drug Name |
G-207 virus construct
|
||||
| Synonyms |
HrR3; G-207; G-47; G-47delta; G-207 virus construct, Catherex; G-207 virus construct, MediGene; HSV mutants (glioma), NCI; Oncolytic herpes simplex virus (glioma), Catherex/MediGene
|
||||
| Indication | Glioma [ICD9: 191; ICD10:C71] | Phase 1/2 | [1] | ||
| Company |
MediGene Inc
|
||||
| CAS Number |
CAS 126098-20-2
|
||||
| Target and Pathway | |||||
| Target(s) | Ribonucleoside-diphosphate reductase | Target Info | Inhibitor | [2], [3] | |
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT00028158) Safety and Effectiveness Study of G207, a Tumor-Killing Virus, in Patients With Recurrent Brain Cancer. U.S. National Institutes of Health. | ||||
| REF 2 | Utilizing tumor hypoxia to enhance oncolytic viral therapy in colorectal metastases. Ann Surg. 2004 Jun;239(6):892-9; discussion 899-902. | ||||
| REF 3 | Anti-tumor effect of oncolytic herpes simplex virus G47delta on human nasopharyngeal carcinoma. Chin J Cancer. 2011 Dec;30(12):831-41. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.